AQR Capital Management LLC Grows Position in Pediatrix Medical Group, Inc. $MD

Key Points

• AQR Capital Management LLC increased its stake in Pediatrix Medical Group by 3.3%, owning approximately 0.53% of the company worth $6,466,000 after acquiring an additional 14,799 shares.
• Pediatrix Medical Group reported earnings per share (EPS) of $0.53 for the last quarter, surpassing the consensus estimate of $0.42, but noted a 7.1% year-over-year revenue decline.
• Multiple financial institutions, including BNP Paribas Financial Markets and Deutsche Bank AG, have significantly raised their stakes in Pediatrix Medical Group, reflecting increased institutional interest in the company.

AQR Capital Management LLC grew its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 3.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 458,880 shares of the company's stock after acquiring an additional 14,799 shares during the quarter. AQR Capital Management LLC owned about 0.53% of Pediatrix Medical Group worth $6,466,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Principal Financial Group Inc. boosted its position in shares of Pediatrix Medical Group by 6.2% during the 1st quarter. Principal Financial Group Inc. now owns 586,190 shares of the company's stock valued at $8,494,000 after acquiring an additional 34,266 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Pediatrix Medical Group by 219.5% during the 1st quarter. GAMMA Investing LLC now owns 2,569 shares of the company's stock valued at $37,000 after acquiring an additional 1,765 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Pediatrix Medical Group by 194.0% during the 1st quarter. SG Americas Securities LLC now owns 38,405 shares of the company's stock valued at $556,000 after acquiring an additional 25,343 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of Pediatrix Medical Group by 2.9% during the 1st quarter. Russell Investments Group Ltd. now owns 219,184 shares of the company's stock valued at $3,176,000 after acquiring an additional 6,127 shares during the last quarter. Finally, Deutsche Bank AG boosted its position in shares of Pediatrix Medical Group by 53.1% during the 4th quarter. Deutsche Bank AG now owns 74,023 shares of the company's stock valued at $971,000 after acquiring an additional 25,663 shares during the last quarter. Institutional investors own 97.71% of the company's stock.

Pediatrix Medical Group Stock Up 0.2%

Shares of NYSE MD traded up $0.04 during trading on Wednesday, reaching $16.17. The company had a trading volume of 554,621 shares, compared to its average volume of 715,026. Pediatrix Medical Group, Inc. has a 12-month low of $10.39 and a 12-month high of $17.67. The stock has a market cap of $1.41 billion, a PE ratio of 12.53 and a beta of 1.30. The business's 50-day moving average is $14.91 and its 200 day moving average is $14.21. The company has a quick ratio of 1.80, a current ratio of 1.80 and a debt-to-equity ratio of 0.70.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported $0.53 EPS for the quarter, topping analysts' consensus estimates of $0.42 by $0.11. Pediatrix Medical Group had a return on equity of 18.94% and a net margin of 5.66%.The firm had revenue of $468.84 million for the quarter, compared to analysts' expectations of $464.37 million. During the same period in the prior year, the firm posted $0.34 earnings per share. The company's quarterly revenue was down 7.1% on a year-over-year basis. As a group, equities analysts forecast that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on MD shares. Leerink Partners boosted their target price on Pediatrix Medical Group from $14.50 to $17.00 and gave the stock a "market perform" rating in a research report on Friday, September 5th. UBS Group boosted their target price on Pediatrix Medical Group from $16.00 to $16.50 and gave the stock a "neutral" rating in a research report on Thursday, August 14th. Wall Street Zen downgraded Pediatrix Medical Group from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Finally, Zacks Research upgraded Pediatrix Medical Group to a "strong-buy" rating in a research report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $16.79.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.